Insmed
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 912
- Market Cap
- $13.2B
- Introduction
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Clinical Trials
146
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (121 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: TPIP F2Drug: TPIP F3
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 42
- Registration Number
- NCT07102316
An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Conditions
- Pulmonary Arterial HypertensionPulmonary Hypertension, Interstitial Lung Disease
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Insmed Incorporated
- Registration Number
- NCT06939647
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 204
- Registration Number
- NCT06685835
- Locations
- 🇺🇸
USA001, Phoenix, Arizona, United States
🇺🇸USA007, Sacramento, California, United States
🇺🇸USA026, Coral Gables, Florida, United States
A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT06344728
- Locations
- 🇺🇸
USA001, Dallas, Texas, United States
Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 18
- Registration Number
- NCT06238856
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
Insmed Reports Strong Q2 2025 Results with ARIKAYCE Growth and Brensocatib Approval Pending
Insmed achieved $107.4 million in ARIKAYCE revenue for Q2 2025, representing 19% growth compared to the same quarter in 2024, with growth across all geographic regions.
Insmed Opens Cambridge R&D Facility Focused on Synthetic Rescue Platform for Rare Diseases
Princess Anne officially opened Insmed's new 17,000 square foot research facility in Cambridge, UK, dedicated to synthetic rescue technology for rare diseases.
Insmed's TPIP Achieves Breakthrough Results in Phase 2b PAH Trial with 35% Reduction in Pulmonary Vascular Resistance
Insmed's treprostinil palmitil inhalation powder (TPIP) met its primary endpoint with a statistically significant 35% placebo-adjusted reduction in pulmonary vascular resistance in patients with pulmonary arterial hypertension.
Non-Cystic Fibrosis Bronchiectasis Market Expected to Reach USD 7.5 Billion by 2035, Driven by Novel Therapies
The Non-Cystic Fibrosis Bronchiectasis (NCFB) market is projected to grow from USD 1.7 billion in 2024 to USD 7.5 billion by 2035, representing a robust CAGR of 14.62%.
EMA Evaluates Fast-Track Status for Three Novel Therapeutics from Scholar, Insmed, and Soleno
• The European Medicines Agency is reviewing accelerated assessment requests for three innovative drugs - apitegromab, brensocatib, and diazoxide choline - based on their potential major public health impact. • Scholar Rock's apitegromab, Insmed's brensocatib, and Soleno's diazoxide choline are being evaluated for their therapeutic innovation potential in addressing significant unmet medical needs. • The fast-track designation, if granted, would expedite the regulatory review process for these promising therapeutics, potentially bringing them to patients more quickly.
AN2 Therapeutics Shifts Phase 3 MAC Lung Disease Trial to Quality of Life Endpoint
AN2 Therapeutics has selected Quality of Life-Bronchiectasis (QOL-B) respiratory domain as the new primary efficacy endpoint for their Phase 3 EBO-301 trial in treatment-refractory MAC lung disease.
FDA Grants Priority Review to Brensocatib for Non-Cystic Fibrosis Bronchiectasis Treatment
The FDA has accepted Insmed's New Drug Application for brensocatib, setting a PDUFA target action date of August 12 under Priority Review designation.
Insmed's Gene Therapy Receives IND Clearance, Aiming to Transform DMD Treatment
Insmed's novel gene therapy candidate for Duchenne Muscular Dystrophy (DMD) has received IND clearance, paving the way for clinical trials.
Insmed's Brensocatib NDA Accepted by FDA with Priority Review; Anticipated Launch in Q3 2025
The FDA has accepted Insmed's New Drug Application for brensocatib in bronchiectasis, granting Priority Review with a PDUFA target action date of August 12, 2025.
NCFB Pipeline Shows Promise with Over 15 Companies Developing New Therapies
• The non-cystic fibrosis bronchiectasis (NCFB) market is experiencing growth due to rising prevalence and increased awareness, leading to early diagnosis and treatment. • Over 15 companies are actively developing more than 15 NCFB drugs, aiming to improve the treatment landscape for this chronic lung condition. • Key players like Insmed, AstraZeneca, and Verona Pharma are advancing promising therapies such as brensocatib, benralizumab and ensifentrine through clinical trials. • Recent clinical trial milestones, including Phase III results for brensocatib and Phase II enrollment for AP-PA02, signal progress in addressing unmet needs in NCFB treatment.